X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://www.businesswire.com/news/home/20231208002957/en/Genentech%E2%80%99s-Kadcyla-Is-the-First-Targeted-Therapy-to-Show-Significant-Overall-Survival-Benefit-in-People-With-HER2-Positive-Early-Stage-Breast-Cancer-With-Residual-Invasive-Disease-After-Neoadjuvant-Treatment
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427
https://www.biospace.com/article/astrazeneca-and-novartis-post-positive-data-in-breast-cancer-at-esmo/?s=71
http://www.pharmatimes.com/news/nice_backs_roches_kadcyla_for_her2-positive_early_breast_cancer_1340087
https://www.nice.org.uk/news/article/nice-draft-guidance-recommends-new-treatment-option-for-people-with-early-breast-cancer
https://www.reuters.com/article/us-roche-china/roche-wins-approval-for-cancer-drug-kadcyla-in-fast-growing-china-market-idUSKBN1ZL237
http://www.globenewswire.com/news-release/2019/12/19/1962685/0/en/WindMIL-Therapeutics-Announces-Clinical-Research-Collaboration-with-Bristol-Myers-Squibb-to-Evaluate-Marrow-Infiltrating-Lymphocytes-MILs-in-Combination-with-nivolumab-Opdivo-for-T.html
http://www.pmlive.com/pharma_news/ema_backs_adjuvant_use_of_roches_breast_cancer_adc_kadcyla_1320584
Market Place
Share 
